prikaz prve stranice dokumenta Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma
  Download
PDF 215.94 KB
Scientific paper - Original scientific paper
Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma
Gynecologic Oncology, 105 (2007), 3; 727-735. https://doi.org/10.1016/j.ygyno.2007.02.012
Pavelić, Jasminka; Radaković, Branko; Pavelić, Krešimir

Cite this document

Pavelić, J., Radaković, B. & Pavelić, K. (2007). Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecologic Oncology, 105. (3), 727-735. doi: 10.1016/j.ygyno.2007.02.012

Pavelić, Jasminka, et al. "Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma." Gynecologic Oncology, vol. 105, no. 3, 2007, pp. 727-735. https://doi.org/10.1016/j.ygyno.2007.02.012

Pavelić, Jasminka, Branko Radaković and Krešimir Pavelić. "Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma." Gynecologic Oncology 105, no. 3 (2007): 727-735. https://doi.org/10.1016/j.ygyno.2007.02.012

Pavelić, J., Radaković, B. and Pavelić, K. (2007) 'Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma', Gynecologic Oncology, 105(3), pp. 727-735. doi: 10.1016/j.ygyno.2007.02.012

Pavelić J, Radaković B, Pavelić K. Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecologic Oncology [Internet]. 2007 June [cited 2024 July 08];105(3):727-735. doi: 10.1016/j.ygyno.2007.02.012

J. Pavelić, B. Radaković and K. Pavelić, "Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma", Gynecologic Oncology, vol. 105, no. 3, pp. 727-735, June 2007. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:508377. [Accessed: 08 July 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma
AuthorJasminka Pavelić
AuthorBranko Radaković
AuthorKrešimir Pavelić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
OBJECTIVE: To investigate the consequences of IGF proteins dysfunction in development of endometrial adenocarcinomas. ----- METHODS: The expression of IGF 2 and IGF 1R was correlated with the expression of IGF 2R and apoptosis rate in 59 human endometrial adenocarcinomas, 10 endometrial hyperplasias and 7 normal tissues. The presence of mutations in the IGF 2R gene was followed in 46 adenocarcinomas. We also examined the effect of IGF 1 receptor blockage on cancer cell proliferation. In groups of either IGF 2-positive or IGF 2-negative tumors (stages III and IV) the expression of IGF 1 and IGF 1R was correlated with cell proliferation index and telomerase activity. ----- RESULTS: The expression of IGF 2 and IGF 1R was much higher in malignant tissue of stages III and IV than in tumors of stages I and II and normal or hyperplastic endometrium. This correlated with a decreased apoptosis rate and IGF 2R expression. Eight adenocarcinomas expressed biallelic mutation of the IGF 2R gene. The specific inhibition of IGF 1R and IGF 2 decreased tumor cell proliferation in IGF 2/IGF 1R-positive tumors. Furthermore, the positive correlation between increased expression of IGF 1 and IGF 1R proteins and increased telomerase activity and cell proliferation index was found in both IGF 2-negative and IGF 2-positive tumors. ----- CONCLUSION: Our data suggest that IGF 1, IGF 2 and their receptors are involved in the progression of endometrial adenocarcinomas. As cancer cell proliferation can be abrogated by blocking mRNA or protein products of these genes, tumors with extensive involvement of the IGF 2 pathway would be candidates for the therapeutics strategies aimed at interference with this pathway.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleGynecologic Oncology
Numberingvol. 105, no. 3, pp. 727-735
p-ISSN0090-8258
DOIhttps://doi.org/10.1016/j.ygyno.2007.02.012
URN:NBNurn:nbn:hr:105:508377
Publication2007-06
Document URLhttp://doi.org/10.1016/j.ygyno.2007.02.012
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 08:41:22